A Novel Model Based on Serum Biomarkers to Predict Primary Non-Response to Infliximab in Crohn’s Disease

A Novel Model Based on Serum Biomarkers to Predict Primary Non-Response to Infliximab in Crohn’s Disease

BackgroundInfliximab is effective in inducing and maintaining remission in patients with Crohn’s disease (CD), but primary non-response (PNR) occurs in 10-30% of cases. We investigated whether serum biomarkers are effective in predicting PNR in patients with CD.MethodsFrom January 2016 to April 2020...

Full description

Bibliographic Details
Main Authors:	Li Li, Rirong Chen, Yingfan Zhang, Gaoshi Zhou, Baili Chen, Zhirong Zeng, Minhu Chen, Shenghong Zhang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-07-01
Series:	Frontiers in Immunology
Subjects:	Crohn’s disease primary non-response infliximab serum biomarkers prediction
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2021.646673/full

Similar Items

Serum Levels of Infliximab and Anti-Infliximab Antibodies in Brazilian Patients with Crohn’s Disease
by: Luis Eduardo Miani Gomes, et al.
Published: (2019-04-01)

Refractory Duodenal Crohn's Disease Successfully Treated with Infliximab
by: You Lim Kim, et al.
Published: (2014-01-01)

Early intestinal obstruction after infliximab therapy in Crohn’s disease
by: Mitsuro Chiba, et al.
Published: (2019-08-01)

Adenocarcinoma de recto y ano en paciente con enfermedad de Crohn tratado con infliximab Adenocarcinoma of the rectum and anus in a patient with Crohn´s disease treated with infliximab
by: J. Egea Valenzuela, et al.
Published: (2010-08-01)

Successful Treatment of Postoperative Fistula with Infliximab in a Patient with Crohn's Disease
by: Seong Yeon Jeong, et al.
Published: (2014-01-01)

Development and Validation of an Interleukin-6 Nomogram to Predict Primary Non-response to Infliximab in Crohn’s Disease Patients
by: Yueying Chen, et al.
Published: (2021-04-01)

Infliximab‐induced seizures in a patient with Crohn’s disease: a case report
by: Zhijie Lv, et al.
Published: (2021-04-01)

Long-Term Clinical Outcomes of Korean Patient With Crohn's Disease Following Early Use of Infliximab
by: Nam Hee Kim, et al.
Published: (2014-10-01)

Long-Term Clinical Remission in Biologically Naïve Crohn’s Disease Patients with Adalimumab Therapy, Including Analyses of Switch from Adalimumab to Infliximab
by: Tsutomu Mizoshita, et al.
Published: (2016-06-01)

Cortical Vein Thrombosis after Infliximab Treatment for Crohn’s Disease
by: Saeed Razmeh, et al.
Published: (2021-03-01)

Retreatment and maintenance therapy with infliximab in fistulizing Crohn' disease Retratamiento y tratamiento de mantenimiento con infliximab en la enfermedad de Crohn fistulizante
by: L. Rodrigo, et al.
Published: (2004-08-01)

Microbial and metabolic features associated with outcome of infliximab therapy in pediatric Crohn’s disease
by: Yizhong Wang, et al.
Published: (2021-01-01)

Loss of Response to Long-Term Infliximab Therapy in Children with Crohn’s Disease
by: George Alex, et al.
Published: (2013-10-01)

Predictors of response to infliximab in patients with fistulizing Crohn's disease Factores predictivos de respuesta a infliximab en pacientes con enfermedad de Crohn fistulizante
by: M. Luna-Chadid, et al.
Published: (2004-06-01)

Serum Biomarkers for Inflammatory Bowel Disease
by: Peng Chen, et al.
Published: (2020-04-01)

Treatment persistence during therapeutic sequences with adalimumab and infliximab in the treatment of Crohn's disease
by: Carlos Taxonera, et al.

Trough level of infliximab is useful for assessing mucosal healing in Crohn's disease: a prospective cohort study
by: Akihiro Koga, et al.
Published: (2018-04-01)

Efficacy of ustekinumab against infliximab-induced psoriasis and arthritis associated with Crohn’s disease
by: Matsumoto S, et al.
Published: (2018-07-01)

Co-existence of relapsing polychondritis and Crohn disease treated successfully with infliximab
by: Hye-In Jung, et al.
Published: (2021-01-01)

Clinical efficacy of adalimumab versus infliximab and the factors associated with recurrence or aggravation during treatment of anal fistulas in Crohn's disease
by: Cheng-Chun Ji, et al.
Published: (2017-04-01)

Efficacy of adalimumab in patients with crohn's disease and failure to infliximab therapy: a clinical series Eficacia de Adalimumab en pacientes con enfermedad de Crohn y fracaso previo a la terapia con Infliximab: resultados de una serie clínica
by: Patricia Cordero-Ruiz, et al.
Published: (2011-06-01)

ADALIMUMAB INDUCTION AND MAINTAINING REMISSION FOR CROHN’S DISEASE IN PATIENT WHO LOST RESPONSE TO INFLIXIMAB. Case report
by: Ivaylo Vazharov, et al.
Published: (2016-12-01)

Infliximab improves quality of life in the short-term in patients with fistulizing Crohn's disease in clinical practice Infliximab mejora la calidad de vida en pacientes con enfermedad de Crohn fistulosa
by: V. Cadahia, et al.
Published: (2004-06-01)

Evaluation of Infliximab Effects on Gastrointestinal Bleeding in Crohn’s Disease Using Double-Balloon Endoscopy
by: Manzurul Chowdhury, et al.
Published: (2009-07-01)

Infliximab-induced psoriasis in a patient with crohn′s disease
by: Iqbal Bukhari, et al.
Published: (2015-01-01)

Infliximab- and Immunosuppressant-Resistant Crohn’s Disease Successfully Treated with Adsorptive Granulocyte Apheresis Combined with Prednisolone
by: Munenori Itagaki, et al.
Published: (2012-02-01)

Erythema dyschromicum perstans (ashy dermatosis) during the treatment with infliximab in a child with Crohn disease
by: Michał Sobjanek, et al.
Published: (2014-03-01)

Formyl Peptide Receptors and Annexin A1: Complementary Mechanisms to Infliximab in Murine Experimental Colitis and Crohn’s Disease
by: Marina de Paula-Silva, et al.
Published: (2021-09-01)

Adalimumab versus infliximab in treating post-operative recurrence of Crohn's disease: a national cohort study
by: Carmen-Monica Preda, et al.

Decrease in Mucosal IL17A, IFNγ and IL10 Expressions in Active Crohn’s Disease Patients Treated with High-Dose Vitamin Alone or Combined with Infliximab
by: Mia Bendix, et al.
Published: (2020-11-01)

Seven Weeks of High-Dose Vitamin D Treatment Reduces the Need for Infliximab Dose-Escalation and Decreases Inflammatory Markers in Crohn’s Disease during One-Year Follow-Up
by: Mia Bendix, et al.
Published: (2021-03-01)

Bioelectrical impedance analysis-based nomogram construction for predicting secondary loss of response to infliximab in bio-naïve Crohn’s disease patients
by: Chen Yueying, et al.
Published: (2021-10-01)

Anti-TNF treatment and miliary tuberculosis in Crohn’s disease
by: Milenković Branislava, et al.
Published: (2011-01-01)

Early Serum Infliximab Levels in Pediatric Ulcerative Colitis
by: Jennifer C. C. deBruyn, et al.
Published: (2021-07-01)

Arteritic anterior ischemic optic neuropathy (AAION) in a patient with Crohn´s disease treated with Infliximab.
by: Elisabet Martín García, et al.
Published: (2016-10-01)

EFFICACY OFINFLIXIMABIN THE TREATMENTOF CROHN’S DISEASEIN CHILDREN
by: E. G. Tsimbalova, et al.
Published: (2012-01-01)

Loss of response and frequency of adverse events in patients with ulcerative colitis and Crohn’s disease when switching from the original infliximab to its biosimilars
by: O. V. Knyazev, et al.
Published: (2021-02-01)

Severe Acute Respiratory Distress Syndrome during Infliximab Therapy in a Patient with Crohn Disease
by: Johanna Schoehl, et al.
Published: (2016-10-01)

Effect of infliximab therapy on serum and fecal biomarker levels in pediatric patients with inflammatory bowel disease
by: Ellis, Montana
Published: (2021)

Fecal Microbiota Transplantation is a Promising Switch Therapy for Patients with Prior Failure of Infliximab in Crohn’s Disease
by: Qianqian Li, et al.
Published: (2021-05-01)

Cannot write session to /tmp/vufind_sessions/sess_omfkdsu9sg16gkngvtfmoadmhe